Medicinal Cannabis Ineffective for Anxiety, Depression & PTSD: Lancet Study

The largest review to date of medicinal cannabis has found no evidence it effectively treats anxiety, depression, or post-traumatic stress disorder (PTSD), despite widespread use for these conditions. Published in The Lancet, the analysis raises questions about current prescribing practices and highlights the need for more rigorous research into the potential benefits and harms of cannabinoids.

Roughly 27 percent of adults aged 16-65 in the United States and Canada report using cannabis for medical purposes, with approximately half of those users citing mental health symptoms as their primary reason, according to the study. This new research, led by Dr. Jack Wilson from the University of Sydney’s Matilda Centre, suggests that for many, this self-medication may not be providing the relief they seek – and could potentially be detrimental.

What the Analysis Examined

The comprehensive review encompassed data from 54 randomized controlled trials conducted over a 45-year period (1980-2025). Researchers systematically analyzed the results to assess both the effectiveness and safety of cannabinoids across a broad spectrum of mental health conditions. The study, funded by the NHMRC, considered a wide range of cannabinoids, the active compounds in cannabis, and their impact on various mental health outcomes. The full study is available in The Lancet Psychiatry.

Potential Harms and Delayed Care

Dr. Wilson cautioned that the routine use of medicinal cannabis for anxiety, depression, and PTSD could inadvertently worsen mental health outcomes. He specifically pointed to an increased risk of psychotic symptoms and the development of cannabis use disorder, as well as the potential for delaying access to more effective, evidence-based treatments. This concern echoes warnings from major medical organizations regarding the limited regulation and uncertainty surrounding the safety and efficacy of cannabis products.

Limited Benefits for Specific Conditions

While the findings were largely negative for the core mental health conditions studied, the researchers did identify some limited evidence suggesting potential benefits for specific conditions. These included cannabis use disorder itself (helping with dependency), autism spectrum disorder, insomnia, and tic or Tourette’s syndrome. However, Dr. Wilson emphasized that the quality of evidence supporting these uses was generally low. He stressed that, without robust medical or psychological support, the use of medicinal cannabis for these conditions is often not justified.

The study also noted that medicinal cannabis may be beneficial in managing certain physical health conditions, such as reducing seizures associated with some forms of epilepsy, alleviating spasticity in individuals with multiple sclerosis, and managing specific types of pain. However, the evidence for mental health disorders remained significantly weaker.

Substance Use Disorders: A Mixed Picture

The review’s analysis of substance use disorders revealed a complex picture. Cannabis-based treatments showed some promise in assisting individuals struggling with cannabis dependence, potentially functioning similarly to methadone in opioid-use disorder treatment. When administered alongside psychological therapy, an oral formulation of cannabis was shown to reduce cannabis smoking. However, a concerning finding emerged regarding cocaine-use disorder: cannabis use actually increased cravings in this population, suggesting it should not be considered as a treatment option and could, in fact, exacerbate the addiction. ScienceDaily provides further details on this aspect of the research.

Autism Spectrum Disorder: A Note of Caution

The study indicated some evidence that medicinal cannabis could help reduce symptoms in individuals with autism spectrum disorder. However, researchers were quick to emphasize that autism is a highly variable condition, with no single, universal experience. This finding should be interpreted with caution and not generalized across the entire autism spectrum.

What Does This Mean for Patients?

These findings do not necessarily mean that cannabis has *no* effect on mental health symptoms for some individuals. However, they do highlight the lack of robust scientific evidence to support its widespread use as a treatment for anxiety, depression, or PTSD. Patients currently using medicinal cannabis for these conditions should discuss their treatment plan with a qualified healthcare professional to explore alternative, evidence-based options. It’s crucial to remember that self-treating with cannabis can potentially delay access to effective care and may even worsen symptoms in some cases.

The Need for Stricter Regulation and Further Research

The rapid increase in medicinal cannabis use and prescribing has prompted calls for stricter regulation and oversight. Experts emphasize the need for standardized product quality, clear labeling, and comprehensive monitoring of potential adverse effects. Scientific American’s coverage details the call for more rigorous standards akin to those applied to conventional medications.

Ongoing Research and Future Directions

Dr. Wilson emphasized that this study provides a crucial foundation for future research. Further investigation is needed to explore the potential benefits and risks of specific cannabinoids, different formulations, and various routes of administration. Well-designed, large-scale clinical trials are essential to determine whether cannabis or its components can play a safe and effective role in the treatment of mental health conditions. The researchers also suggest a need for ongoing surveillance to monitor the impact of medicinal cannabis use on mental health outcomes in the real world.

The findings underscore the importance of relying on evidence-based treatments for mental health disorders and engaging in open and honest conversations with healthcare providers about all treatment options.